Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer

Joanna M. Brell, Khalid Matin, Terry Evans, Robert L. Volkin, Gauri J. Kiefer, James J. Schlesselman, Shelley Dranko, Linda Rath, Amy Schmotzer, Diana Lenzner, Ramesh K. Ramanathan

Research output: Contribution to journalArticle

31 Scopus citations

Abstract

Background: There is no standard second-line therapy for advanced pancreatic cancer (APC). We evaluated the epidermal growth factor receptor (EGFR) inhibitor gefitinib and docetaxel in a phase II study following gemcitabine failure. Methods: EGFR overexpression was not required. The initial docetaxel dose was 75 mg/m2 on day 1 every 21 days. Due to febrile neutropenia in 8 of the first 18 patients, the dose was reduced to 60 mg/m 2. Gefitinib, 250 mg/day orally, was given continuously. Results: Forty-one patients received treatment and were evaluable. Febrile neutropenia was seen in 11 patients (27%), with most events occurring at the docetaxel dose of 75 mg/m2 (8 of 18 patients). Common treatment-related grade 3/4 toxicities were: fatigue (7%), nausea (7%), diarrhea (5%) and vomiting (2%). There was 1 partial response and stable disease in 19 patients. Time to progression was 1.8 months and median survival was 4.5 months (95% CI 2.9-5.7). Conclusion: The tolerability and feasibility of second-line therapy for APC was demonstrated. The combination of gefitinib and docetaxel showed evidence of limited efficacy.

Original languageEnglish (US)
Pages (from-to)270-274
Number of pages5
JournalOncology
Volume76
Issue number4
DOIs
StatePublished - Mar 1 2009

Keywords

  • Docetaxel
  • Gefitinib
  • Pancreatic cancer
  • Phase II, second-line therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Brell, J. M., Matin, K., Evans, T., Volkin, R. L., Kiefer, G. J., Schlesselman, J. J., Dranko, S., Rath, L., Schmotzer, A., Lenzner, D., & Ramanathan, R. K. (2009). Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer. Oncology, 76(4), 270-274. https://doi.org/10.1159/000206141